The potential for regression of renal scarring

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 3, 2003, Pages 223-225

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; EXTRACELLULAR MATRIX; HUMAN; KIDNEY SCAR; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE REGENERATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES; NEPHRONS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0038629110     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200305000-00001     Document Type: Review

References (21)

1. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
2. Fogo A, Yoshida Y, Glick AD, et al. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988; 82:322-330.
3. Fogo A. Progression and potential regression of glomerulosclerosis. Kidney Int 2001; 59:804-819.
4. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110:341-350.
5. Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989; 298:564-567.
6. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure: less of one, more the other? Am J Hypertens 1988; 1:335-347.
7. Pesce C, Schmidt K, Fogo A, et al. Glomerular size and the incidence of renal disease in African Americans and Caucasians. J Nephrol 1994; 7:355-358.
8. Keller G, Zimmer G, Mall G, et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348:101-108.
9. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000; 58:674-683.
10. Ma LJ, Nakamura S, Nakamura I, et al. High dose angiotensin II type 1 receptor antagonist and angiotensin converting enzyme inhibitor in regression of glomerulosclerosis [abstract]. J Am Soc Nephrol 2002; 13:342A.
11. Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22:399-406.
12. Aldigier J, Ma L-J, Kanjanabuch T, et al. Regression of existing glomerulosclerosis by inhibition of aldosterone [abstract]. Lab Invest 2003; 83:265A.
13. Remuzzi A, Gagliardini E, Donadoni C, et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62:885-894.
14. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13:2898-2908.
15. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61:1684-1695.
16. Katz A, Caramori ML, Sisson-Ross S, et al. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 2002; 61:2058-2066.
17. Nishida M, Fujinaka H, Matsusaka T, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002; 110:1859-1868.
18. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41:31-36.
19. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
20. Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110:371-379.
21. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69-75.